HIV treatment may take a toll on the brain: Study

Image
IANS New York
Last Updated : Dec 17 2016 | 11:22 AM IST

Antiretroviral drugs have been life-changing therapies for HIV patients, but they can have significant side effects including neuronal degeneration, which can be manifested as forgetfulness, confusion and behavioural and motor changes, says a study.

Certain protease inhibitors, among the most effective HIV drugs, lead to the production of the peptide beta amyloid, often associated with Alzheimer's disease, the study found.

"Protease inhibitors are very effective antiviral therapies, but they do have inherent toxicities," said senior author on the study Kelly Jordan-Sciutto, Professor at University of Pennsylvania School of Dental Medicine in the US.

The drugs prompt an increase in levels of the enzyme that cleaves the amyloid precursor protein, APP, to produce beta amyloid, which is responsible for the damage to neurons.

Notably, inhibiting that enzyme, called BACE1, protected human and rodent brain cells from harm, suggesting that targetting this mechanism with a new drug could minimise damage to neurons in patients on antiretroviral therapies.

"Our findings may cause us to rethink how we're using these drugs and even consider developing an adjunctive therapy to reduce some of these negative effects," Jordan-Sciutto noted.

To determine whether and how neuronal damage arises from drug treatment and to ascertain the enzyme BACE1's role, the team investigated the effects of protease inhibitors in two animal models, then probed the mechanism of action in cells in culture.

The findings appeared in the American Journal of Pathology.

--IANS

gb/vm

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 17 2016 | 11:10 AM IST

Next Story